Fresh from the biotech pipeline—2017

Fresh from the biotech pipeline—2017, Published online: 22 January 2018; doi:10.1038/nbt.4068

A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.

中文翻译：

---

2017 年刚刚从生物技术管道中出来。


刚刚从生物技术管道中出来——2017

积极的监管环境，加上包括美国首个基因疗法在内的大量药物批准，在 2017 年提振了该行业。FDA 的灵活性和对市场竞争的关注可能会在来年激励创新者。克里斯·莫里森报道。